Abstract: The present invention relates to the new impurities of Fesoterodine, Fesoterodine symmetric dimer impurity and asymmetric dimer impurity, process for preparing and isolating thereof. The invention also deals with analytical standards and analytical methods used for the control of the production process and final quality of Fesoterodine.

Abstract: The present invention relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering Antagonist A or another pharmaceutically acceptable salt thereof, optionally in combination with another treatment, to a subject in need thereof. The present invention also relates to methods for treating and preventing ophthalmological disease and disorders, comprising administering an anti-C5 agent (e.g., ARC1905), optionally in combination with another treatment, to a subject in need thereof.

Abstract: The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of Fesoterodine from O-benzyl tolterodine.

Abstract: The present invention relates to the new impurities of Fesoterodine, Fesoterodine symmetric dimer impurity and asymmetric dimer impurity, process for preparing and isolating thereof. The invention also deals with analytical standards and analytical methods used for the control of the production process and final quality of Fesoterodine.

Abstract: This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof.

Abstract: Computer system to facilitate video gaming comprising a processing unit and a computer readable medium coupled to the processing unit comprising instructions executable by the processing unit. Instructions are for a video game that receives first input events triggered by operation of first input devices used to navigate the video game. Instructions are for input adaptation module to facilitate playing the same video game using the second input device that is free from facility to provide the first input events using the first input devices. The input adaptation module receives second input events triggered by operation of the second input device used to navigate the game. It generates the first input events from the second input events, based at least upon the game-specific translation mapping between input events receivable from the second input device and input events receivable from the first input devices. Associated method is also provided.

Abstract: The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of fesoterodine and pharmaceutically acceptable salts thereof which involves use and preparation of R(+)benzyl tolterodine and fumarate salt of R(+)-[4-benzyloxy-3-(3-diisopropylamino-1-phenylpropyl)-phenyl]-methanol.

Abstract: The present invention relates to an improved process for preparing Bosentan of formula (I).

Abstract: A convertible table with two folding legs and two base legs. Each folding leg is rotatably connected to one end of a connection bar, the other end of each connection bar rotatably connected to a respective base leg. A first end of a frame member, which includes a table surface and a writing board, is rotatably attached to top ends of the base legs. A second end of the frame member is rotatably attached to top ends of the folding legs. In a first position, the writing board faces downward and a conventional table is provided with the table surface. In a second position, the folding legs, guided by the connection bars, rotate relative to the frame member and are locked to sides of the frame member by respective locking mechanisms. In the second position, the writing board extends in an upright position and is accessible.

Abstract: The present invention provides a process for preparing Teriflunomide of formula (I).

Abstract: The present invention relates to a process for preparing Teriflunomide of formula (I).

Abstract: The present invention relates to process for the preparation of Prasugrel HCl having formula (I).

Abstract: The present invention provides a new polymorph Form I of Teriflunomide sodium and a process for preparation thereof. The present invention provides an amorphous form of Teriflunomide sodium and a process for preparation thereof. The present invention provides a new polymorph Form I of Teriflunomide potassium and a process for preparation thereof. The present invention provides an amorphous form of Teriflunomide potassium and a process for preparation thereof. The present invention also provides particle size of Teriflunomide and its salts.

Abstract: This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a PDGF antagonist and a VEGF antagonist to a mammal in need thereof.

Abstract: Disclosed herein is a system and method for producing T cells from stem cell populations. Specifically exemplified herein is a culture system and method that produces CD4 cells and/or T cell subtypes from a CD4 lineage using a sample of hematopoietic stem cells. Adult hematopoietic precursor/stem cells (HPC) are progenitors to all lineages of immune cells. There has been limited success in generating functional CD4 T cells with this convenient culture system. Also disclosed herein is a novel stromal cell line expressing DL1, interleukin-7 (IL-7), and FMS-like tyrosine kinase 3 ligand (Flt3-L). This improved culture system can greatly facilitate the study of late T cell development and enables immunotherapeutic applications.

Abstract: The invention provides compositions and methods for treating ocular disorders, such as angiogenesis-associated disorders, by administering a combination of an inhibitor of VEGF activity and an inhibitor of ?5?1 integrin activity.

Abstract: The present invention provides a process for preparing Teriflunomide of formula (I).

Abstract: The present invention relates to a process for preparing Teriflunomide of formula (I).

Abstract: A catheter assembly is provided having an inner member and an outer member extending along a longitudinal axis, the inner member and the outer member having a coaxial configuration and dimensioned for relative axial movement. The outer member may include an anti rotation member adapted to engage with a longitudinal slot formed on the inner member so as to maintain rotational alignment between inner member and outer member. The inner member can be made with a proximal portion made from a tubing such as hypotubing or a coil tubing. The inner member also may be made with a proximal portion made with a support mandrel. A coil tubing can be utilized to form the guide wire receiving member which is attached to the inner member.

Abstract: Bifurcated delivery assemblies provide bilateral access to first and second branch lumens extending from a main body space or lumen in a patient. One or more interventional devices are combined with the delivery assemblies for delivery s into one or both of the branch lumens. Bilateral renal stenting or embolic protection procedures are performed using the combination delivery/interventional device assemblies. Fluids may also be injected or aspirated from the assemblies. A bifurcated catheter has a first fluid port located on one bifurcation branch, a second fluid port located on a second branch of the bifurcation, and a third fluid port positioned so as to be located within a vena cava when the first and second ports are positioned bilaterally within first and second renal veins.